IL2RB and neoplasm: In regard to the primary tumor volume as shown in Fig. 4, there was enhanced efficacy of Ad-p53 + CD122/132, Ad-p53 + anti-PD-1, and Ad-p53 + CD122/132 + anti-PD-1 treatments compared to any of the therapies alone.